XML 27 R17.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Debt obligations | 3 Months Ended
--- | ---
Mar. 31, 2018
Debt obligations | NOTE 11 – Debt obligations: Short-term debt:
|  | Weighted average interest rate as of March 31, 2018 |  | Maturity |  |  | March 31, 2018 |  |  | December 31, 2017 |
|  |  |  |  |  |  | (U.S. $ in millions) |
Term loan JPY 28.3 billion (5) |  | JPY LIBOR+0.25% |  |  | 2018 |  |  | $ | — |  |  | $ | 251 |
Convertible debentures |  | 0.25% |  |  | 2026 | * |  |  | 514 |  |  |  | 514 |
Other |  | 11.68% |  |  | 2018 |  |  |  | 2 |  |  |  | 1 |
Current maturities of long-term liabilities |  |  |  | 786 |  |  |  | 2,880 |
Total short term debt |  |  | $ | 1,302 |  |  | $ | 3,646 |
* | Net-share settlement feature exercisable at any time.
Long-term debt includes the following:
|  | Weighted average interest rate as of March 31, 2018 |  | Maturity |  | March 31, 2018 |  |  | December 31, 2017 |
|  | % |  |  |  | (U.S. $ in millions) |
Senior notes EUR 1,750 million |  | 0.38% |  | 2020 |  | $ | 2,152 |  |  | $ | 2,095 |
Senior notes EUR 1,500 million |  | 1.13% |  | 2024 |  |  | 1,837 |  |  |  | 1,788 |
Senior notes EUR 1,300 million |  | 1.25% |  | 2023 |  |  | 1,593 |  |  |  | 1,550 |
Senior notes EUR 1,000 million (3) |  | 2.88% |  | 2019 |  |  | — |  |  |  | 1,199 |
Senior notes EUR 900 million (1) |  | 4.50% |  | 2025 |  |  | 1,109 |  |  |  | — |
Senior notes EUR 750 million |  | 1.63% |  | 2028 |  |  | 915 |  |  |  | 891 |
Senior notes EUR 700 million (1) |  | 3.25% |  | 2022 |  |  | 863 |  |  |  | — |
Senior notes EUR 700 million |  | 1.88% |  | 2027 |  |  | 859 |  |  |  | 837 |
Senior notes USD 3,500 million |  | 3.15% |  | 2026 |  |  | 3,492 |  |  |  | 3,492 |
Senior notes USD 3,000 million |  | 2.20% |  | 2021 |  |  | 2,997 |  |  |  | 2,996 |
Senior notes USD 3,000 million |  | 2.80% |  | 2023 |  |  | 2,992 |  |  |  | 2,992 |
Senior notes USD 2,000 million |  | 1.70% |  | 2019 |  |  | 2,000 |  |  |  | 2,000 |
Senior notes USD 2,000 million |  | 4.10% |  | 2046 |  |  | 1,984 |  |  |  | 1,984 |
Senior notes USD 1,500 million (3) |  | 1.40% |  | 2018 |  |  | — |  |  |  | 1,500 |
Senior notes USD 1250 million (2) |  | 6.00% |  | 2024 |  |  | 1,250 |  |  |  | — |
Senior notes USD 1250 million (2) |  | 6.75% |  | 2028 |  |  | 1,250 |  |  |  | — |
Senior notes USD 844 million |  | 2.95% |  | 2022 |  |  | 863 |  |  |  | 864 |
Senior notes USD 789 million |  | 6.15% |  | 2036 |  |  | 781 |  |  |  | 781 |
Senior notes USD 700 million |  | 2.25% |  | 2020 |  |  | 700 |  |  |  | 700 |
Senior notes USD 613 million |  | 3.65% |  | 2021 |  |  | 623 |  |  |  | 624 |
Senior notes USD 588 million |  | 3.65% |  | 2021 |  |  | 587 |  |  |  | 587 |
Senior notes CHF 450 million |  | 1.50% |  | 2018 |  |  | 472 |  |  |  | 461 |
Senior notes CHF 350 million |  | 0.50% |  | 2022 |  |  | 367 |  |  |  | 360 |
Senior notes CHF 350 million |  | 1.00% |  | 2025 |  |  | 368 |  |  |  | 360 |
Senior notes CHF 300 million |  | 0.13% |  | 2018 |  |  | 314 |  |  |  | 308 |
Fair value hedge accounting adjustments |  |  | (16 | ) |  |  | (2 | )
Total senior notes |  |  | 30,352 |  |  |  | 28,367 |
Term loan USD 2.5 billion (4) |  | LIBOR +1.1375% |  | 2018 |  |  | — |  |  |  | 285 |
Term loan USD 2.5 billion (4) |  | LIBOR +1.50% |  | 2017-2020 |  |  | — |  |  |  | 2,000 |
Term loan JPY 58.5 billion (5) |  | JPY LIBOR +0.55% |  | 2022 |  |  | — |  |  |  | 519 |
Term loan JPY 35 billion (6) |  | 1.42% |  | 2019 |  |  | — |  |  |  | 311 |
Term loan JPY 35 billion (6) |  | JPY LIBOR +0.3% |  | 2018 |  |  | — |  |  |  | 311 |
Total loans |  |  | — |  |  |  | 3,426 |
Debentures USD 15 million (7) |  | 7.20% |  | 2018 |  |  | — |  |  |  | 15 |
Other |  | 7.31% |  | 2026 |  |  | 5 |  |  |  | 5 |
Total debentures and others |  |  | 5 |  |  |  | 20 |
Less current maturities |  |  | (786 | ) |  |  | (2,880 | )
Derivative instruments |  |  | 16 |  |  |  | 2 |
Less debt issuance costs |  |  | (137 | ) |  |  | (106 | )
Total long-term debt |  | $ | 29,450 |  |  | $ | 28,829 |
Debt development
(1) | In March 2018, Teva Pharmaceutical Finance Netherlands II B.V., a Teva finance subsidiary, issued senior notes in an aggregate principal amount of €1.6 billion.
(2) | In March 2018, Teva Pharmaceutical Finance Netherlands III B.V., a Teva finance subsidiary, issued senior notes in an aggregate principal amount of $2.5 billion.
(3) | In March 2018, Teva redeemed in full its $1.5 billion 1.4% senior notes due in July 2018 and its €1.0 billion 2.88% senior notes due in April 2019.
(4) | During the first quarter of 2018, Teva prepaid approximately $2.3 billion principal amount of the remaining term loan facilities.
(5) | During the first quarter of 2018, Teva prepaid in full JPY 86.8 billion principal amount of the outstanding term loan facilities of which JPY 28.3 billion were in short-term debt as of December 31, 2017.
(6) | During the first quarter of 2018, Teva prepaid in full JPY 70 billion of its 1.42% and JPY LIBOR+0.3% outstanding term loans.
(7) | During the first quarter of 2018, Teva prepaid in full $15 million of its outstanding debentures.
Long term debt was issued by several indirect wholly-owned subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts (as defined), if any. Long term debt as of March 31, 2018 is effectively denominated (taking into consideration cross currency swap agreements) in the following currencies: U.S. dollar 64%, euro 34% and Swiss franc 2%. Teva’s principal sources of short-term liquidity are its existing cash investments, liquid securities and available credit facilities, primarily its $3 billion syndicated revolving credit facility (“RCF”), which was not utilized as of March 31, 2018, as well as internally generated funds. In connection with the requirements of the RCF, the Company entered into negative pledge agreements with certain banks and institutional investors. Under the agreements, the Company and its subsidiaries have undertaken not to register floating charges on assets in favor of any third parties without the prior consent of the banks, to maintain certain financial ratios, including the requirement to maintain compliance with a net debt to EBITDA ratio, which becomes more restrictive over time, and to fulfill other restrictions, as stipulated by the agreements. As of March 31, 2018, the Company did not have any outstanding debt under the RCF, which is our only debt subject to the net debt to EBITDA covenant Assuming utilization of the RCF, and under specified circumstances, including non-compliance with such covenants and the unavailability of any waiver, amendment or other modification thereto and the expiration of any applicable grace period thereto, substantially all of the Company’s debt could be negatively impacted by non-compliance with such covenants. The Company has sufficient resources to meet its financial obligations in the ordinary course of business for at least twelve months from the date of the release of this Quarterly Report.

X
- Definition The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -URI http://asc.fasb.org/topic&trid=2208564 + Details
Name: | us-gaap_DebtDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration